Amgen Announces Voting Results of Annual Meeting of Stockholders
PROVIDENCE, R.I.--(BUSINESS WIRE)--May 9, 2007--Amgen
(NASDAQ:AMGN) today announced results of voting at the company's
Annual Meeting of Stockholders, held at the Westin Providence hotel in
Providence, R.I. Approximately 86.9 percent of outstanding shares were
represented at the meeting.
The director nominees, Frank J. Biondi, Jr., Jerry D. Choate,
Frank C. Herringer and Gilbert S. Omenn, were each reelected to
Amgen's Board of Directors, receiving at least 96.5 percent of 'For'
votes. With the reelection of these directors, Amgen currently has 10
With 97.5 percent of 'For' votes, stockholders ratified Ernst &
Young as Amgen's independent registered public accountants for the
year ending Dec. 31, 2007. Stockholders also approved
company-sponsored proposals to amend the company's Restated
Certificate of Incorporation and Bylaws to permit the declassification
of the Board of Directors. Stockholders holding approximately 98
percent of the company's outstanding shares cast votes in favor of
these two proposals, which results in the company's directors being
required to stand for reelection each year, beginning with the
company's 2008 Annual Meeting of Stockholders.
Stockholders rejected a proposal that would require the company to
post an animal welfare policy on its website and issue a report to
stockholders tracking the company's adherence to the policy. The
proposal received only five percent of 'For' votes. Stockholders also
rejected a proposal that would require the company to publish an
annual sustainability report disclosing the company's social and
environmental practices. The proposal received 9.7 percent of 'For'
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science's promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis and other serious illnesses. With
a deep and broad pipeline of potential new medicines, Amgen remains
committed to advancing science to dramatically improve people's lives.
To learn more about our pioneering science and our vital medicines,
CONTACT: Amgen, Thousand Oaks
David Polk, 805-490-0661 (media)
Kristen Davis, 805-447-3008 (media)
Arvind Sood, 805-447-1060 (investors)